Last updated:
Author(s):
Rachel A Hoffing, Aimee M Deaton, Aaron M Holleman, Lynne Krohn, Philip J LoGerfo, Mollie E Plekan, Sebastian Akle Serrano, Paul Nioi, Lucas D Ward
Publish date:
1 January 2024
Journal:
Biocomputing
PubMed ID:
38160284

Abstract

A single gene can produce multiple transcripts with distinct molecular functions. Rare-variant association tests often aggregate all coding variants across individual genes, without accounting for the variants’ presence or consequence in resulting transcript isoforms. To evaluate the utility of transcript-aware variant sets, rare predicted loss-of-function (pLOF) variants were aggregated for 17,035 protein-coding genes using 55,558 distinct transcript-specific variant sets. These sets were tested for their association with 728 circulating proteins and 188 quantitative phenotypes across 406,921 individuals in the UK Biobank. The transcript-specific approach resulted in larger estimated effects of pLOF variants decreasing serum cis-protein levels compared to the gene-based approach (pbinom ≤ 2×10-16). Additionally, 251 quantitative trait associations were identified as being significant using the transcript-specific approach but not the gene-based approach, including PCSK5 transcript ENST00000376752 and standing height (transcript-specific statistic, P = 1.3×10-16, effect = 0.7 SD decrease; gene-based statistic, P = 0.02, effect = 0.05 SD decrease) and LDLR transcript ENST00000252444 and apolipoprotein B (transcript-specific statistic, P = 5.7×10-20, effect = 1.0 SD increase; gene-based statistic, P = 3.0×10-4, effect = 0.2 SD increase). This approach demonstrates the importance of considering the effect of pLOFs on specific transcript isoforms when performing rare-variant association studies.

Related projects

1. The primary scientific goal of the research is to apply human genetics to the identification of new drug targets, the validation of existing targets…

Institution:
Regeneron Genetics Center, LLC, United States of America

The primary scientific goal of this research project is to apply multiplex proteomic profiling of 56,000 UK Biobank plasma samples to facilitate the identification of…

Institution:
Pfizer Inc, USA, United States of America

All projects